Your browser doesn't support javascript.
loading
Clinical observation of L-Thyroxine combined with selenium yeast in treating lymphocytic thyroiditis / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics ; (6): 49-51, 2017.
Article Dans Chinois | WPRIM | ID: wpr-511660
ABSTRACT
Objective To analyze the clinical effect of L-thyroxine combined with selenium yeast in patients with lymphocytic thyroiditis.Methods The clinical data of 96 patients with lymphocytic thyroiditis from March 2015 to September 2016 was analyzed retrospectively.The cases were divided into study group(48 cases)and control group(48 cases)according to double-blind method.The control group were treated with levothyroxine and the study group were treated with levothyroxine combined with selenium yeast.Free tetraiodothyronine(FT4),free triiodothyronine(FT3),thyrotropin(TSH),thyroglobulin antibody(TGAb),serum thyroid peroxidase antibody(TGAb)and serum thyroid peroxidase(TPOAb),the level of peripheral blood T cell subsets and the total effective rate between the two groups were compared.Results After treatment,the levels of FT4,FT3,TSH,TGAb and TPOAb in the two groups were significantly better than those before treatment(P<0.05).FT4,FT3,TSH,TGAb,TPOAb levels in the study group were significantly better than that in the control group(P<0.05).Compared with the control group,the T lymphocyte subsets of the study group after treatment were significantly better(P<0.05).Compared with the control group,the total effective rate of the study group was significantly higher(P<0.05).Conclusion The effect of L-thyroxine combined with selenium yeast in the treatment of lymphocytic thyroiditis patients is very significant.The treatment method is worthy of promotion in the clinical treatment.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Essai clinique contrôlé langue: Chinois Texte intégral: Chinese Journal of Biochemical Pharmaceutics Année: 2017 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Essai clinique contrôlé langue: Chinois Texte intégral: Chinese Journal of Biochemical Pharmaceutics Année: 2017 Type: Article